Indian pharma eyes pride of place, regulation Achilles heel
Pharamaceutical | December 22, 2016
India is on track to cement its position next year as a source of safe, effective and quality medicines at affordable prices, but a “growing trust deficit” with the government and regulatory headwinds can pose a serious roadblock to this journey. The USD 32-billion generic-driven Indian pharma industry is eyeing a sea of opportunities as global demand for safe and quality drugs rises, especially in developed economies such as the US, the EU and Japan.